Search results
Results From The WOW.Com Content Network
On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG. [15] On April 9, 2019, Alcon completed a 100% spin-off from Novartis. [4] [16] [17] The new standalone company is worth up to 28 billion Swiss francs. [18]
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Novartis is the world's first largest in life sciences and agribusiness markets. [6] It is also the second-largest pharmaceutical company by market cap in 2019. [126] Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [127]
Novartis (NVS) has worked aggressively to purchase Alcon (ACL), a major eye-care company, from Nestlé. The deal-making started a couple of years ago when Novartis shelled out $10.4 billion to ...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Official website. DealStreetAsia is a Singapore-based financial news website, founded in 2014 by Joji Thomas Philip. It is a financial news platform tracking private equity, venture capital activity, deal flows, initial public offers, investments, fund-raising, startups and targets to be the go-to destination portal for deal activity in Asia.
By John Miller ZURICH (Reuters) - Swiss eyecare company Alcon made its debut on the SIX Swiss Exchange on Tuesday with a market capitalisation of more than $25 billion after a shareholder spin-off ...
Coordinates: 1.3040°N 103.7891°E. The Novartis Institute for Tropical Disease ( NITD) was a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical ...